Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells

Japanese Journal of Cancer Research

Volumn 92, Issue 7, 2001, Pages 778-784

  Matsumoto, Y ^a   Takano, H ^a   Kunishio, K ^a   Nagao, S ^a   Fojo, T ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

CK II; cMOAT; MDR 1; MRP; Topoisomerase II

Indexed keywords

AMINOACRIDINE; CASEIN KINASE II; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; MEMBRANE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG; VINCRISTINE;

ADAPTATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOMA CELL; CELL ISOLATION; CLONE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESISTANCE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; OBSERVATION; PRIORITY JOURNAL;

EID: 0034879831     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2001.tb01161.x     Document Type: Article

References (36)

1. The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II
2. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells
3. Structure and mechanism of DNA topoisomerase II
4. Role of topoisomerase II in modifying epipodophyllotoxin-induced DNA damage
5. DNA topoisomerase: Enzymes that control DNA conformation
6. DNA topoisomerase
7. Mechanistic aspects of DNA topoisomerases
8. Mechanisms of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide
9. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
10. DNA topoisomerase II as a target of antineoplastic drug therapy
11. Novel HeLa topoisomerase II is the II-b isoform: Complete coding sequence and homology with other type II topoisomerases
12. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes
13. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
14. Differences between normal and ras-transformed NIH-3T3 cells on expression of the 170 kD and 180 kD forms of topoisomerase II
15. Single-strand conformational polymorphism analysis of the Mr 170,000 isozyme of DNA topoisomerase II in human tumor cells
16. Non P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug induced DNA damage and reduced levels of topoisomerase II
17. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line
18. Overexpression of multidrug resistance associated protein increases resistance to natural product drugs
19. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P glycoprotein or MRP overexpression
20. Increased rate of VP-16 efflux in a murine leukemia cell line overexpressing the multidrug resistance associated protein gene
21. Congenital jaundice in rats with a mutation in a multidrug resistance associated protein gene
22. A human canalicular multi-specific organic anion transporter gene is overexpression in cisplatin resistant human cancer cell lines with decreased drug accumulation
23. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells
24. Two independent amsacrine resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II
25. Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines
26. The regulation of DNA topoisomerase II by casein kinase II
27. Casein kinase II phosphorylates the eukaryote-specific c-terminal domain of topoisomerase II in vitro
28. Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster
29. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase II alpha in yeast
30. Serine 1524 is a major site of phosphorylation on human topoisomerase IIa protein in vivo and is a substrate for casein kinase II in vitro
31. Cell cycle phase-specific phosphorylation of human topoisomerase IIα
32. New colorimetric cytotoxicity assay for anticancer-drug screening
33. Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype
34. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
35. Alterations in the topoisomerase IIa gene, messenger RNA, and subcellular protein distribution as well reduced expression of the DNA topoisomerase IIβ enzyme in mitoxantrone-resistant HL-60 human leukemia cell line
36. Pharmacological characterization of multidrug resistant MRP transfected human tumor cells